Royalty Report: Medical, Device, Supply – Collection: 260430

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 5

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 5

Primary Industries

  • Medical
  • Device
  • Supply
  • Surgical
  • Disease
  • Wound Care

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 260430

License Grant
Licensor grants the exclusive license to Manufacture, use and Distribute Products for Permitted Clinical Applications within the Territory. All Products must be Manufactured using Modified Starch at a Licensee Facility in the United States or at any Licensee Facility outside of the United States approved by Licensor in writing.

For the Manufacturing IP, Licensor shall deliver to Licensee all documents, memoranda, schematics, diagrams and other information (whether in written, electronic or other form) disclosing and describing all methods and processes necessary or useful for Manufacturing the Products using Modified Starch

License Property
Licensor has the exclusive right to create biocompatible, absorbable polysaccharides using the AMPâ„¢ technology.

The patent is Modified Starch Material of Biocompatible Hemostasis.

PerClot(R) is a novel polysaccharide hemostatic agent used in surgery.  PerClot is a medical device composed of absorbable modified polymer (AMP(R)) particles and delivery applicators. AMP particles are derived from purified plant starch. PerClot contains no human or animal components. It is intended for use as an absorbable hemostatic system to control bleeding during surgical procedures or following traumatic injuries.

Field of Use
All permitted indications for use of the Products obtained by Licensor that are for class III medical devices as of the Effective Date of this Agreement (whether such indications could be downgraded or modified in the future to be for class I or class II medical devices). Such permitted indications include use in surgical procedures or injuries as an adjunct hemostat when control of bleeding from capillary, venous, or arteriolar vessels by pressure, ligature, and other conventional means is either ineffective or impractical.
Contra-indications specified in the PerClot IFU are not Permitted Clinical Applications.  Notwithstanding the foregoing, Permitted Clinical Applications do not include topical hemostasis, first aid, woundcare, all non-absorbable hemostatic applications ( defined as class I or class II medical device) and anti-adhesion applications.

PerClot is a unique, absorbable powder hemostat that is indicated for use in surgical procedures, including cardiac, vascular, orthopedic, spinal, neurological, gynecological, ENT and trauma surgery as an adjunct hemostat when control of bleeding from capillary, venous, or arteriolar vessels by pressure, ligature, and other conventional means is either ineffective or impractical.

IPSCIO Record ID: 5286

License Grant
Under our license agreements, the Licensee has exclusive rights to manufacture, market and distribute all current and future sizes of the patented Angio-Seal for hemostatic puncture closures for cardiovascular use worldwide.
License Property
Angio-Seal(TM) Vascular Closure Device (Angio-Seal) is designed to seal and close femoral artery punctures made during diagnostic and therapeutic cardiovascular catheterizations.  The Angio-Seal STS Plus device offers quick, consistent and predictable hemostasis (cessation of bleeding) at the puncture site. Its fast, secure closure reduces the risk of complications and can allow patients to resume activities sooner than if managed with manual compression.  The Angio-Seal STS Plus device includes a small bio-resorbable anchor, suture and collagen pad. The anchor is placed in the artery through a small delivery system and secured against the artery's interior wall. Then the collagen pad, which is positioned on the outside of the artery, is bound together with the suture to form a secure seal. The self-tightening suture enables the physician to finalize the closure procedure immediately. Unlike many other vascular closure devices, all components of the Angio-Seal STS Plus device are fully absorbed with 60 to 90 days, so no foreign material permanently remains in the body.  The angio-Seal STS plus platform is composed of an absorbable collagen sponge and a specially designed absorbable polymer anchor connected by an absorbable self-tightening suture. The device seals and sandwiches the arteriotomy between its two primary components, the anchor and the collagen sponge. Hemostasis is achieved primarily through mechanical means and is supplemented by the platelet inducing properties of the collagen.
Field of Use
The rights granted apply for hemostatic puncture closures for cardiovascular use.

IPSCIO Record ID: 72974

License Grant
The agreement licensed certain bone wax rights to develop products in the field of bone remodeling, based on patent number 7,074,425 for use in the human skeletal system.
Field of Use
The field of use is bone remodeling in the human skeletal system.  The license agreement excludes the fields of (1) a resorbable hemostat (resorbable bone wax), (2) a resorbable orthopedic hemostat (bone wax) and antimicrobial dressing, and (3) veterinary orthopedic applications.

IPSCIO Record ID: 7008

License Grant
Licensor hereby grants to Licensee the worldwide, sole exclusive License, including the right to grant subLicenses, under the Patent Rights and to practice the Licensed Processes.
License Property
This application generally relates to medical devices and more specifically relates to medical devices for use in the surgical treatment of hyperproliferative diseases affecting the spinal cord.
Field of Use
Field of Use shall mean treatment of Spinal cord injury.

IPSCIO Record ID: 27675

License Grant
The agreement licensed certain bone wax rights to develop products in the field of bone remodeling, based on patent number 7,074,425 for use in the human skeletal system.  The license agreement excludes the fields of (1) a resorbable hemostat (resorbable bone wax), (2) a resorbable orthopedic hemostat (bone wax) and antimicrobial dressing, and (3) veterinary orthopedic applications. In January 2014, Licensee received 510k approval for their first product under the license, a bioactive bone graft putty and bone graft extender.  In February 2014, Licensor granted a Commercial License to Licensee according to the terms of the development and license agreement.
License Property
The Licensor acquired patent 7,074,425 in September 2009.  It is for a resorbable bone wax and delivery system for orthopedic bone void fillers. The patent offers innovative, safe and effective resorbable orthopedic products that are complementary to the already existing Licensor products.  The bone wax and delivery system address issues such as bone wax granuloma and the cost-effective delivery of materials that manage bone wound healing. The resorbable orthopedic products covered by the patent are (a) a resorbable orthopedic hemostat (resorbable bone wax) used to stop blood flow, (b) a delivery system for osteogenic/osteoinductive orthopedic products (bone void fillers), and (c) the formula as a delivery system for bone growth factors.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.